The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was ...

The U.S. FDA has approved Durvalumab in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). The approval was based ...

The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...

Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...

Combination significantly improved disease-free survival in phase III trial ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...

FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...

Pelvic floor physical therapists share the best exercises to strengthen your pelvic floor. Here's how to do them.

Raise awareness this May for bladder cancer, its symptoms, and the importance of early detection to save lives.

I’m 70 years old, and my whole family is prone to edema, varicose veins and deep vein thrombosis due to venous insufficiency.